(2) make such database available on the public 
website of the Department of Health and Human 
Services. 
(b) COVERED INFORMATION.—The information relat-
ing to Federal support referred to in subsection (a)(1) in-
cludes all contracts, funding agreements, licensing ar-
rangements, other transactions, and other arrangements 
entered into by or on behalf of the Federal Government 
and tax benefits provided with respect to research and de-
velopment, and manufacturing, of a drug (including a bio-
logical product), cell or gene therapy, or medical device 
intended to be manufactured, used, designed, developed, 
modified, repurposed, licensed, or procured to diagnose, 
mitigate, prevent, treat, or cure COVID–19, including the 
following: 
(1) Licensing agreements pursuant to section 
207 or 209 of title 35, United States Code. 
(2) Cooperative research and development 
agreements and licensing agreements pursuant to 
section 3710a of title 15, United States Code. 
(3) Funding agreements, as defined under sec-
tion 201 of title 35, United States Code. 
(4) Transactions, contracts, grants, cooperative 
agreements, other agreements, and other arrange-
VerDate Sep 11 2014 
15:45 Mar 24, 2021
Jkt 019200
PO 00000
Frm 00003
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
pamtmann on DSKBC07HB2PROD with BILLS
ments entered into pursuant to the following stat-
utes: 
(A) The Public Health Service Act (42 
U.S.C. 201 et seq.), including sections 301, 
319L, 421, and 480 of such Act (42 U.S.C. 
241, 247d–7e, 285b–3, 287a). 
(B) Section 105 of the National Institutes 
of Health Reform Act of 2006 (42 U.S.C. 
284n). 
(C) Chapter 139 of title 10, United States 
Code (10 U.S.C. 2351 et seq.), including sec-
tions 2358, 2371, 2371a, 2371b, and 2373. 
(5) Grants, contracts, and other transactions 
pursuant to section 2371, 2371a, or 2371b of title 
10, United States Code. 
(6) Procurement contracts and other agree-
ments pursuant to section 2373 of title 10, United 
States Code. 
(c) INFORMATION REQUIRED.—Notwithstanding any 
other provision of law, the Federal officials referred to in 
subsection (a) shall include in the database under sub-
section (a), with regard to each contract, funding agree-
ment, licensing agreement, other transaction, other ar-
rangement, or tax benefit described in subsection (b), at 
least the following information: 
VerDate Sep 11 2014 
15:45 Mar 24, 2021
Jkt 019200
PO 00000
Frm 00004
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
pamtmann on DSKBC07HB2PROD with BILLS
(1) The agency, program, institute, or other 
Federal Government entity providing the Federal 
grant, cooperative agreement, or other support. 
(2) The amount and period of Federal financial 
support with an itemized breakdown. 
(3) Other Federal nonfinancial support, includ-
ing the use of Federal personnel, Federal facilities, 
and Federal equipment. 
(4) The grant number, if applicable. 
(5) Associated clinical trial data, upon trial 
completion. 
(6) Associated patents and patent applications, 
specifying— 
(A) any Federal ownership in such patents 
and patent applications; 
(B) the expiration date of such patents 
and filing dates of such patent applications; and 
(C) the numbers of such patents and pat-
ent applications. 
(7) Associated periods of marketing exclusivity 
under Federal law and the durations of such peri-
ods. 
(8) The corporation, nonprofit organization, 
academic institution, person, or other entity receiv-
ing the Federal support. 
VerDate Sep 11 2014 
15:45 Mar 24, 2021
Jkt 019200
PO 00000
Frm 00005
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
pamtmann on DSKBC07HB2PROD with BILLS
(9) Any products (including repurposed prod-
ucts) approved, authorized, or cleared for marketing, 
or for which marketing approval, authorization, or 
clearance is being sought, the development of which 
was aided by Federal support, including— 
(A) the names of such products; 
(B) the prices of such products; and 
(C) the current and anticipated manufac-
turing capacity to produce such products. 
(10) The full terms of the contract, funding 
agreement, licensing agreement, other transaction, 
or other arrangement described in subsection (b). 
(d) FORMAT OF INFORMATION.—The database under 
subsection (a) shall be— 
(1) searchable and filterable according to the 
categories of information described in subsection (c); 
and 
(2) presented in a user-friendly format. 
(e) TIMING.—The database under subsection (a) 
shall be— 
(1) made publicly available not later than 1 
month of the date of enactment of this Act; and 
(2) updated not less than every 2 weeks. 
(f) DISCLOSURE.— 
VerDate Sep 11 2014 
15:45 Mar 24, 2021
Jkt 019200
PO 00000
Frm 00006
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
pamtmann on DSKBC07HB2PROD with BILLS
(1) IN GENERAL.—Notwithstanding any other 
provision of law, to the extent necessary for an offi-
cial referred to in subsection (a) to carry out this 
section, such official may require entities receiving 
Federal support referred to in subsection (a)(1) to 
disclose to the official any information relating to 
such Federal support and required to be included in 
the database under subsection (a). 
(2) INTERMEDIARY
COOPERATION.—Any ar-
rangement entered into by the Federal Government 
with an entity providing for such entity to enter into 
contracts, licensing agreements, grants, other trans-
actions, or other arrangements with third parties on 
behalf of the Federal Government shall require such 
entity to disclose in a timely manner any informa-
tion necessary for the Federal Government to fulfill 
its duties under this Act. With respect to any such 
arrangement in place as of the date of enactment of 
this Act, an official referred to in subsection (a) may 
require the entity to disclose to the official any infor-
mation required to be included in the database 
under subsection (a). 
(3) PENALTY FOR NONDISCLOSURE.—If an en-
tity that is required to disclose information pursuant 
to paragraph (1) or (2) fails to disclose such infor-
VerDate Sep 11 2014 
15:45 Mar 24, 2021
Jkt 019200
PO 00000
Frm 00007
Fmt 6652
Sfmt 6201
E:\BILLS\H1391.IH
H1391
pamtmann on DSKBC07HB2PROD with BILLS
mation by the date that is two weeks after the date 
on which the official requests such information, or 
by such reasonable deadline as the official may 
specify, whichever is sooner, then such entity shall 
be liable to the United States for a civil penalty in 
an amount not to exceed $10,000 for each day on 
which such failure continues. 
Æ 
VerDate Sep 11 2014 
15:45 Mar 24, 2021
Jkt 019200
PO 00000
Frm 00008
Fmt 6652
Sfmt 6301
E:\BILLS\H1391.IH
H1391
pamtmann on DSKBC07HB2PROD with BILLS